While others focus on creating new drugs, CellMosaic is transforming how medicine is delivered, using precision targeting to maximize effectiveness and minimize side effects.
Our team believes that smarter drug delivery is the driving force behind advancing medicine. During last week’s investor webinar, Dr. Yumei Huang showcased how our precision technology is leading this transformation. The future of medicine isn’t defined by what we deliver. It’s how we deliver it.
If you're interested in how biotech is making cancer therapy more precise and less toxic, the full session is now available on YouTube:
Why CellMosaic, Why Now
Rather than betting on a single drug's success, we generate revenue by providing essential tools and services that many drug developers need. With our technology now proven through 500+ global partnerships and growing market demand for precision medicine solutions, we’re positioned to expand our impact across multiple treatment areas.
As our SEC-regulated crowdfunding campaign nears its close, Dr. Huang outlined why CellMosaic’s proven technology and revenue model offers a unique opportunity in biotech investing.
Learn more about investing: https://www.startengine.com/offering/cellmosaic
Webinar Highlights
When Treatment Hurts More Than Helps [03:45-05:30]
Dr. Huang shared how her experience supporting her mother through cancer treatments, navigating both the disease and the side effects, ignited CellMosaic's mission to transform medicine. "Traditional chemotherapy is nonspecific and affects all fast growing cells," she explained. "We're developing technology to deliver cancer medicine precisely and safely where it's needed."
AqueaTether®: The Science of Precision [08:30-11:15]
Our AqueaTether® technology solves a critical problem by helping drugs stay stable in the bloodstream until reaching their targets.
Recent work published by Massachusetts General Brigham using our product showed promising results in targeting circulating tumor cells while sparing healthy tissue.
The Department of Defense recognized this approach as a breakthrough for making treatments more precise and less harmful. Dr. Huang explained how this same technology can potentially improve treatments beyond cancer, from diabetes to addiction therapy.
Building Scientific Partnerships [21:30-23:45]
- 159 teams developing targeted treatments
- 38 groups creating specialized delivery systems
- 71 organizations advancing diagnostic tools
- 48 distributors across 17 countries
Growing Market Impact [24:15-25:30]
The targeted treatment market shows strong momentum:
- Expected to reach $40B by 2029
- Deal values increased 400% since 2017
- $9.7B in manufacturing opportunities
From the Q&A: Small Team, Big Impact
When asked about CellMosaic's lean approach over 15 years, Dr. Huang emphasized how innovation doesn't require large teams: "You really don't need a lot of people to be innovative. We try to keep the company small and focused, developing the technology needed to expand. Now is the time."
You can watch the full video here: [link]
Join CellMosaic's Mission
We’re raising funds to:
- Build more AqueaTether®-linked drug assets for partnerships
- Develop treatments for preclinical and clinical studies
- Expand global sales of research products
Ready to learn more about investing in CellMosaic's vision for precision medicine? Visit our StartEngine campaign before it closes: https://www.startengine.com/offering/cellmosaic
This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.